Nkarta, Inc. (NKTX)
NASDAQ: NKTX · Real-Time Price · USD
1.545
-0.115 (-6.93%)
Oct 30, 2026, 2:43 PM EDT - Market open
Nkarta Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
106
Market Cap
110.66M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Foghorn Therapeutics | 36.74M |
| Innate Pharma | 11.21M |
| Armata Pharmaceuticals | 5.54M |
| NRx Pharmaceuticals | 3.39M |
| Kazia Therapeutics | 1.27M |
| Outlook Therapeutics | -1.16M |
NKTX News
- 5 weeks ago - Nkarta Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum - Transcripts
- 6 weeks ago - Nkarta Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 7 weeks ago - Nkarta to Participate in September Investor Conferences - GlobeNewsWire
- 7 weeks ago - Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026 - GlobeNewsWire
- 2 months ago - Nkarta price target lowered to $10 from $11 at Stifel - TheFly
- 2 months ago - Nkarta price target lowered to $14 from $16 at H.C. Wainwright - TheFly
- 2 months ago - Nkarta reports Q2 EPS (54c), consensus (36c) - TheFly
- 2 months ago - Nkarta Earnings release: Q2 2026 - Filings